Home > Boards > US Listed > Biotechs > Galera Therapeutics, Inc. (GRTX)

You know that stuff is over my head,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
loanranger Member Profile
Member Level 
Followed By 177
Posts 29,462
Boards Moderated 0
Alias Born 06/30/09
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 7:06:47 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/10/2020 6:04:06 AM
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire Inc. - 11/20/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/17/2020 4:07:24 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2020 7:32:03 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/10/2020 7:08:45 AM
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 11/10/2020 7:00:00 AM
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire Inc. - 11/3/2020 8:00:00 AM
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiati... GlobeNewswire Inc. - 10/27/2020 3:00:10 PM
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419... GlobeNewswire Inc. - 10/23/2020 5:00:10 PM
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with S... GlobeNewswire Inc. - 10/22/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/7/2020 5:02:22 PM
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer GlobeNewswire Inc. - 9/22/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/16/2020 8:08:34 AM
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 fo... GlobeNewswire Inc. - 9/16/2020 8:00:10 AM
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire Inc. - 9/14/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2020 7:02:34 AM
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Plac... GlobeNewswire Inc. - 9/8/2020 8:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 7:32:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 7:11:51 AM
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 8/10/2020 7:00:10 AM
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference GlobeNewswire Inc. - 7/30/2020 8:00:10 AM
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally... GlobeNewswire Inc. - 7/13/2020 5:46:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/22/2020 4:53:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2020 5:48:08 PM
loanranger Member Level  Monday, 09/07/20 10:09:05 PM
Re: PlentyParanoid post# 23
Post # of 27 
You know that stuff is over my head, although the ‘imputation’ of missing values is never good even if it is approved and frequent practice in academic circles. Besides it's over, isn't it?

Galera's Phase 3 (335 participants), started in October 2018, has an Estimated Primary Completion Date of October 2020. When do you think IPIX will have their P3 Actual Study Start Date?



ps. Thanks for the link...I don't have any articles handy.

I'm not questioning the truth of what the Company is saying. I just don't understand it. Quit whining and explain it.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences